Spectrum (SPPI) Beats on Revenue, Misses on EPS

Spectrum Pharmaceuticals, Inc. (SPPI) gained $0.29 to $6.55 in pre-market session Friday after it reported fiscal-fourth quarter earnings.

The biotech firm handed in non-GAAP earnings of $0.09 per share on revenue of $51.9 million, vs. Wall Street estimates of $0.12 per share on revenue of $48.73 million.

For the twelve-month period ended December 31, 2014, the company recorded a narrower net loss of $45.7 million, or 71 cents per share, compared to net loss of $62.1 million, or ($1.02)/shr in fiscal 2013. Total product sales was reported as $186.5 million, a 30% jump yoy.

On valuation measures, Spectrum Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 1.58 million shares, have a median Wall Street price target of $12.00 with a high target of $15.00. Currently ticker boasts 2 ‘Buy’ endorsements, compared to 1 ’Hold’ and no ‘Sell’.

Profitability-wise, SPPI has a t-12 profit and operating margin of (46.53%) and (19.68%), respectively. The $405.43 million market cap company reported $133.2 million in cash in its most recent quarter.

SPPI currently prints a one year loss of about 22.90% and a year-to-date loss of around 10%.

The chart below shows where the equity has traded over the last 52 weeks.

Spectrum Pharmaceuticals Inc. is a biotechnology company focused on developing oncology and hematology drug products. The firm was founded in 1987 and is headquartered in Henderson, Nevada.

Be the first to comment

Leave a Reply

Your email address will not be published.


*